ArticleEuropean radiology experimental2026
Clustering of quantitative CT features identifies HCC subtypes with distinct prognosis and immune signatures.
Article in European radiology experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThere is still a lack of widely applicable biomarkers for immunotherapy in hepatocellular carcinoma (HCC). We aim to identify subtypes using computed tomography (CT) imaging features of HCC and assess their value in predicting prognosis and the effectiveness of immunotherapy. MATERIALS AND
methodsWe used unsupervised consensus clustering based on quantitative contrast-enhanced CT features to identify imaging subtypes and investigated their value in predicting prognosis and the effectiveness of immunotherapy in the discovery (n = 103) and immunotherapy-treated (n = 110) validation cohort. We also developed a gene-based classifier for imaging subtypes and tested their prognostic and biological relevance in two additional gene validation cohorts with publicly available gene expression data but without imaging data (n = 551).
resultsThe imaging subtypes demonstrated significant correlations with overall survival across all cohorts (p = 0.002, p < 0.001) and effectively predicted immunotherapy outcomes, with 1-year progression-free survival rates varying significantly (p < 0.001). Imaging subtypes 1 and 3 with favorable and intermediate immunotherapy responses showed significant activation of B-cells, lymphocyte-mediated immunity, and immune response (adjusted p-value ≤ 0.047, false discovery rate ≤ 0.043). Imaging subtype 2 with poor immunotherapy responses displayed the least activated CD8+ T cells, the lowest cytolytic activity, and the highest infiltration of neutrophil and regulatory T cells. Additionally, type I and II interferon responses were significantly downregulated in imaging subtype 2.
conclusionUnsupervised clustering of CT imaging features identified subtypes with significantly distinct prognosis and immune signatures. The imaging subtypes can serve as a marker for immunotherapy in HCC. RELEVANCE STATEMENT: The imaging subtypes identified in this study demonstrate significant clinical relevance by providing a non-invasive approach to predict prognosis and immunotherapy response for HCC. KEY POINTS: We identified three novel imaging subtypes using unsupervised consensus clustering of quantitative CT imaging features for HCC. Imaging subtypes were independent predictors of overall survival and the effectiveness of immunotherapy for HCC. The imaging subtypes can be used as a marker for immunotherapy in HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.